A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)

Brief summary (registry, in English)

1.Study 2: US/FDA: To evaluate the efficacy of tulisokibart compared with placebo as assessed by the proportion of participants achieving clinical remission per Crohn’s Disease Activity Index score (<150) at Week 12 2.Study 2: EU/EMA: Evaluate the efficacy of tulisokibart compared with placebo as assessed by the proportion of participants achieving clinical remission per stool frequency and abdominal pain score at Week 12 3.Study 2: To evaluate the efficacy of tulisokibart compared with placebo as assessed by the proportion of participants achieving endoscopic response at Week 12

What you commit to

• Study type: Interventional · Phase 3
• Planned participants: 567
• 155 sites in 21 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults, and some adolescents, with moderately to severely active Crohn's disease who did not do well on earlier treatment.

Age

18 years or older. Adolescents aged 16 to under 18 can join only if the country or health authority approves.

Sex

All sexes can join.

Disease stage

Crohn's disease diagnosed at least 3 months before the study, and moderately to severely active.

Earlier treatment

Earlier treatment with one or more drug types (oral locally acting steroids, systemic steroids, immunomodulators, biologic or small molecule advanced therapies) did not work well enough, stopped working, or was not tolerated. Earlier exposure to tulisokibart (MK-7240, PRA023) or another anti-TL1A antibody is not allowed.

Main reasons for not taking part

• Ulcerative colitis or indeterminate colitis
• Hepatitis B, hepatitis C or HIV infection, or active tuberculosis
• History of cancer, unless disease free for at least 5 years (some fully treated skin or cervical cancers excepted)
• Complications of Crohn's disease such as abscess, fulminant colitis, toxic megacolon or a stoma
• Bowel surgery within 3 months of the study

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (155)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details